Future therapy approaches may focus on dual-targeting techniques that simultaneously modulate NF-κB and Nrf2 pathways, aiming to restore redox balance and alleviate chronic inflammation, thereby addressing the underlying molecular pathology of PCOS. This evidence concerns the gene NFKB1 and polycystic ovary syndrome.